Physical examination, serum biochemical, and coagulation abnormalities, treatments, and outcomes for dogs with toxicosis from α-amanitin–containing mushrooms: 59 cases (2006–2019)

Jennifer A. Kaae Pet Emergency and Specialty Center of Marin, San Rafael, CA 94901.

Search for other papers by Jennifer A. Kaae in
Current site
Google Scholar
PubMed
Close
 VMD
,
Robert H. Poppenga California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Robert H. Poppenga in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Ashley E. Hill California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Ashley E. Hill in
Current site
Google Scholar
PubMed
Close
 DVM, MPVM, PhD

OBJECTIVE

To report history, physical examination findings, clinicopathologic abnormalities, treatments, and outcomes of dogs with confirmed α-amanitin toxicosis resulting from ingestion of α-amanitin–containing mushrooms, and to report whether any differences were significant between survivors and nonsurvivors.

ANIMALS

59 dogs.

PROCEDURES

Medical records of all dogs with confirmed α-amanitin toxicosis presented to a northern California emergency and specialty veterinary hospital between January 2006 and July 2019 were reviewed for signalment; body weight; history; physical examination findings including rectal temperature at presentation; results of serum biochemical analyses, coagulation tests, and a test for the detection of α-amanitin in urine; treatments; and outcomes. Differences for each were compared between survivors and nonsurvivors.

RESULTS

Among the 59 dogs, 36 were < 1 year of age; 56 had variable clinical signs that included vomiting, diarrhea, anorexia, and weakness or lethargy; and 22 had rectal temperatures > 39.2°C (102.5°F) at presentation. Cases were seen throughout the calendar year. At presentation, alanine aminotransferase activity was mildly to markedly increased in 97% of dogs, hypoglycemia was noted in 78%, and coagulation times were prolonged in 91%. Most dogs that rapidly decompensated died; however, 13 dogs survived to hospital discharge and completely recovered.

CONCLUSIONS AND CLINICAL RELEVANCE

Ability to recognize dogs with α-amanitin toxicosis on the basis of clinical signs, physical examination findings, and clinicopathologic test results is essential because mushroom ingestion is rarely observed and immediate treatment is necessary. Dogs that have marked hypoglycemia or coagulopathy may have a poor prognosis.

OBJECTIVE

To report history, physical examination findings, clinicopathologic abnormalities, treatments, and outcomes of dogs with confirmed α-amanitin toxicosis resulting from ingestion of α-amanitin–containing mushrooms, and to report whether any differences were significant between survivors and nonsurvivors.

ANIMALS

59 dogs.

PROCEDURES

Medical records of all dogs with confirmed α-amanitin toxicosis presented to a northern California emergency and specialty veterinary hospital between January 2006 and July 2019 were reviewed for signalment; body weight; history; physical examination findings including rectal temperature at presentation; results of serum biochemical analyses, coagulation tests, and a test for the detection of α-amanitin in urine; treatments; and outcomes. Differences for each were compared between survivors and nonsurvivors.

RESULTS

Among the 59 dogs, 36 were < 1 year of age; 56 had variable clinical signs that included vomiting, diarrhea, anorexia, and weakness or lethargy; and 22 had rectal temperatures > 39.2°C (102.5°F) at presentation. Cases were seen throughout the calendar year. At presentation, alanine aminotransferase activity was mildly to markedly increased in 97% of dogs, hypoglycemia was noted in 78%, and coagulation times were prolonged in 91%. Most dogs that rapidly decompensated died; however, 13 dogs survived to hospital discharge and completely recovered.

CONCLUSIONS AND CLINICAL RELEVANCE

Ability to recognize dogs with α-amanitin toxicosis on the basis of clinical signs, physical examination findings, and clinicopathologic test results is essential because mushroom ingestion is rarely observed and immediate treatment is necessary. Dogs that have marked hypoglycemia or coagulopathy may have a poor prognosis.

Introduction

Mushroom ingestion by dogs is common, with > 400 reports from the Pet Poison Helpline from 2018 to 2019 and 2,980 reports of potential mushroom ingestion in animals from the Animal Poison Control Center of the American Society for the Prevention of Cruelty to Animals from 2013 to 2017.1 Although mushroom ingestion is often unnoticed and usually does not result in toxicosis, ingestion of some mushrooms can lead to serious liver damage and death. Hepatotoxicosis has been reported for dogs,2,3 cats,4 and beef calves5 that ingested mushrooms.

The primary hepatotoxins found in mushrooms are amanitins. Amanitins are bicyclic octapeptides, and of the 8 known amanitins, α-amanitin is the most toxic.6 This toxin induces acute liver failure and is found in over 38 different species of mushroom from the genera Amanita (including Amanita phalloides and Amanita ocreata), Galerina, and Lepiota. However, not all Amanita spp have α-amanitin. Amanita phalloides, known as death cap, is the most well-known Amanita sp and is implicated in the majority of cases of α-amanitin toxicosis in people in North America.7 Amanita phalloides, originally native to Europe, is now found worldwide, having been introduced to non-native regions on the roots of imported trees. In many regions, A phalloides is commonly found alongside planted trees, but it is naturalized in California.8 On the west coast of the United States, it is found most commonly alongside oak trees; on the east coast, it is usually associated with pine trees.9 Amanita phalloides typically has a green to yellow cap, but its color can vary (eg, brown, tan, or white) because of environmental conditions.9,10 Clusters of cases occur in certain years because of variations in weather conditions, including precipitation, that impact mushroom growth.8,10 One gram of A phalloides can contain 1.5 to 2.5 mg of α-amanitin,11 and 1 mushroom can contain up to 15 mg of α-amanitin.8 The estimated oral LD50 of α-amanitin for people is 0.1 mg/kg (0.045 mg/lb),11 and the oral LD50 for methyl-α-amanitin for dogs is 0.5 mg/kg (0.23 mg/lb).12

Amanitins are rapidly absorbed from the small intestine through a sodium-dependent bile acid transporter. They travel to the liver via the portal vein and are actively transported into hepatocytes by another bile acid transporter identified in people as OAT-P1B3.13 Amanitins disrupt RNA transcription by inhibiting nuclear RNA polymerase, leading to deficient intracellular protein synthesis and then hepatocellular death.6 Other metabolically active cells, such as intestinal epithelial cells and proximal renal tubular cells, are similarly affected by amanitins.1 Amanitins undergo enterohepatic recirculation and active reabsorption from the small intestine. Amanitins are not highly protein bound, and they are eliminated from the plasma through the kidneys within 48 hours of ingestion.14,15

α-Amanitin toxicosis should be considered in dogs presenting with signs of acute liver failure, especially gastrointestinal signs, hypoglycemia, and marked coagulation abnormalities. Rarely, however, has mushroom exposure been observed, and other toxicoses, including acetaminophen, Sago palm (Cycad spp), xylitol, and blue-green algal microcystins may manifest similarly.16 Because of the difficulty in confirming a diagnosis of α-amanitin toxicosis without known ingestion of a hepatotoxic mushroom, a sensitive antemortem test for the detection of α-amanitin by liquid chromatography–mass spectrometry in urine was developed.17 The test can also be performed with mushroom fragments and other animal specimens, such as vomitus, serum, bile, and fresh (nonpreserved) liver and kidney tissues.

The purposes of the retrospective study reported here were to describe the clinical and clinicopathologic abnormalities, treatments, and outcomes for dogs confirmed with α-amanitin toxicosis and to identify and compare factors that differed between dogs that survived (survivors) and dogs that were euthanized or died (nonsurvivors).

Materials and Methods

Case selection and medical records review

Medical records of dogs with confirmed α-amanitin toxicosis from the Pet Emergency and Specialty Center of Marin (hospital) between January 2006 and December 2019 were reviewed. Some dogs were referred to the hospital from surrounding veterinary clinics, and others presented directly to the hospital through its emergency service. Amanitin toxicosis was confirmed by detection of α-amanitin in specimens submitted to the Toxicology Section of the California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California-Davis.

Urine samples were collected from patients and submitted for testing as soon as amanitin toxicosis was suspected. α-Amanitin analysis was performed with liquid chromatography–mass spectrometry, a sensitive and specific assay with a limit of detection of 1 ppb.17 Results were reported the same day as the samples were submitted and as positive when the concentration of α-amanitin was > 1 ppb, trace when α-amanitin was detected but < 1 ppb, and negative when α-amanitin was not detected. The presence of any α-amanitin was considered noteworthy. The preferred antemortem sample was urine because of α-amanitin's relatively short half-life in serum. On the basis of our experience, kidney tissue was the best postmortem sample because α-amanitin persisted longer in this tissue (vs other specimen types).1 No α-amanitin was detected in the urine of 2 dogs in the present study, but because amanitin toxicosis was strongly suspected, additional samples were submitted for testing. α-Amanitin was subsequently detected in the vomitus of one of these dogs and in bile and kidney tissue collected postmortem from the other dog.

All dogs confirmed with α-amanitin toxicosis were included, and no dog presented > 1 time after diagnosis confirmation. Enrollment was active during the study dates. Records were reviewed retrospectively, and patient signalment, history, physical examination findings; results of serum biochemical analyses, coagulation tests (PT and aPTT), and an amanitin test; treatments; and outcomes were recorded. The following information was specifically recorded: number of hours from the onset of clinical signs to presentation at the hospital or surrounding veterinary clinics (ie, before referral to the hospital); number of hours from onset of clinical signs to resolution (ie, euthanasia, death, or hospital discharge); age; body weight; rectal temperature at presentation; serum ALT activity at presentation and its highest activity during hospitalization; glucose concentration at presentation and its lowest concentration during hospitalization; ALP activity; concentrations of cholesterol, total bilirubin, albumin, and creatinine; BUN concentration; PT at presentation and its highest value during hospitalization; aPTT at presentation and its highest value during hospitalization; and urine α-amanitin test result. Date of onset was categorized by year and season (winter, December to February; spring, March to May; summer, June to August; and fall, September to November).

Statistical analysis

With statistical software,a continuous variables were assessed for normality with the Shapiro-Wilk test. Categorical and continuous variables were then compared between survivors and nonsurvivors (euthanized or died) with a κ2 test for categorical variables, a t test for normally distributed continuous variables, and the Wilcoxon rank sum test for nonnormally distributed continuous variables. Values of P < 0.05 were considered significant.

Results

Signalment

Fifty-nine cases of α-amanitin toxicosis were identified. Twenty-three breeds were represented, including Golden Retriever (n = 13) and Labrador Retriever (10). Thirty-six (61%) dogs were < 1 year of age (range, 2 to 11 months old). The age range for the remaining 23 dogs was 1 to 11 years. Median body weight was 11 kg (24.2 lb; range, 1.4 to 37.7 kg [3.1 to 82.9 lb]).

Initial owner complaints and physical examination findings

Fifty-six (95%) dogs presented with vomiting, weakness, anorexia, lethargy, and diarrhea. Twenty-three (39%) dogs presented with twitches, tremors, seizures, or obtundation secondary to severe hypoglycemia. All dogs presented to the hospital within 36 hours of the onset of clinical signs. Six (10%) of the dogs were initially treated as outpatients for presumptive gastroenteritis but returned to the hospital 12 to 24 hours later because of progressive clinical signs. On initial physical examination, all dogs were assessed to be quiet to depressed or obtunded, and 22 (37%) dogs had rectal temperatures > 39.2°C (102.5°F).

Exposure history and seasonal distribution

Once amanitin toxicosis was suspected, the dog owner was questioned regarding possible exposure to mushrooms. Only 4 owners (7% of cases) reported that they had seen a mushroom in their dog's mouth within 24 hours of presentation. Two other owners had pulled grass and leaves from their dog's mouth but did not see any mushrooms. One owner reported seeing mushroom fragments in the dog's vomitus. In the days preceding the onset of clinical signs, many of the dogs had free access to yards or open spaces where mushrooms were known to grow, but others were in relatively controlled environments (eg, in manicured yards or grassy parks) or always kept on a leash.

Twenty-eight (47%) dogs were seen in the summer, 14 (24%) in the fall, 9 (15%) in the spring, and 8 (14%) in the winter. The season in which toxicosis was diagnosed did not significantly (P = 0.58) differ between dogs that survived and those that were euthanized or died. Forty-five (76%) dogs were seen between May and October. The number of cases varied from year to year, with 21 in 2014, 9 in 2015, and ≤ 5 for the other years.

Clinicopathologic findings

Biochemical analyses were performed on the serum of 57 (97%) dogs at the time of initial evaluation at the hospital; biochemical analyses were not initially performed for 2 dogs that were suspected to have gastroenteritis but were performed when these dogs returned to the hospital within 24 hours of their initial presentation. All dogs with initial serum biochemical analyses had increased ALT activity (range, 144 to 32,395 U/L; reference interval, 18 to 121 U/L; Table 1), and ALT activity for many dogs could not be quantified with the in-hospital biochemistry analyzer without first diluting the serum. Therefore, subsequent samples were submitted to a veterinary diagnostic laboratory for definitive quantification. Alanine aminotransferase activity was recorded many times throughout hospitalization, and 27 of the 59 (46%) dogs ultimately had ALT activity > 10,000 U/L.

Table 1

Median (interquartile [25th to 75th percentile] range) values for specified variables for dogs that were euthanized or died (nonsurvivors) versus those that survived to hospital discharge (survivors) with confirmed α-amanitin toxicosis at an emergency and specialty hospital in northern California between 2006 and 2019.

Variable No. of dogs Reference interval Nonsurvivors Survivors P value
Onset of clinical signs to presentation (h) 59 NA 12.0 (6.0 to 18.0) 12.0 (4.0 to 12.0) 0.53
Onset of clinical signs to resolution (death, euthanasia, or hospital discharge; h) 59 NA 36.0 (28.0 to 56.0) 100.0 (72.0 to 128.0) < 0.01
Age (y) 59 NA 0.7 (0.33 to 5.0) 0.3 (0.2 to 0.8) 0.08
Weight (kg) 59 NA 10.4 (4.8 to 24.8) 11.5 (6.2 to 20.3) 0.84
Temperature at presentation (°C)* 59 37.2–39.2 38.9 (38.0 to 39.5) 39.1 (38.7 to 39.4) 0.33
ALT at presentation (U/L) 57 18–121 1,406 (605 to 5,965) 992 (420 to 3,558) 0.36
Highest ALT during hospitalization (U/L) 59 18–121 9,095 (4,525 to 13,263) 9,027 (4,922 to 12,839) 0.82
Glucose at presentation (mg/dL) 57 74–143 42.0 (27.0 to 67.0) 63.5 (44.5 to 102.5) 0.07
Lowest glucose during hospitalization (mg/dL) 59 74–143 32.0 (23.0 to 41.0) 58.0 (45.5 to 74.0) < 0.01
ALP (U/L) 58 5–160 387.0 (129.0 to 572.0) 469.0 (263.0 to 1,226.0) 0.07
Cholesterol (mg/dL) 54 131–345 204.0 (157.0 to 259.0) 201.0 (182.5 to 285.5) 0.58
Bilirubin (mg/dL) 57 0.0–0.3 2.2 (1.3 to 2.8) 1.3 (0.7 to 3.2) 0.28
Albumin (g/dL) 58 2.7–3.9 2.7 (2.5 to 3.1) 3.0 (2.8 to 3.2) 0.34
Creatinine (mg/dL) 55 0.5–1.5 0.9 (0.5 to 1.4) 0.7 (0.4 to 1.0) 0.13
BUN (mg/dL) 58 9–31 15.0 (12.0 to 21.0) 11.0 (9.0 to 15.0) 0.04
PT at presentation (s) 37 11–14 > 100 (34.0 to > 100) 36.5 (26.0 to 96.0) 0.08
Highest PT during hospitalization (s) 53 11–14 > 100 (> 100 to > 100) 70.0 (42.0 to > 100) 0.02
aPTT at presentation (s) 31 60–93 301.0 (124.0 to > 350.0) 151.0 (97.0 to 208.0) 0.07
Highest aPTT during hospitalization (s) 48 60–93 > 350.0 (210.0 to > 350) 178.0 (139.0 to 301.0) < 0.01

Values of P < 0.05 were considered significant.

To convert °C to °F, multiply by 9/5 and add 32.

NA = Not applicable.

Forty-six of 57 (81%) dogs with serum biochemical analyses at initial evaluation were hypoglycemic (glucose < 74 mg/dL), and 56 of 59 (95%) ultimately had hypoglycemia during hospitalization (Table 1). Hypoglycemia recorded during hospitalization was significantly (P < 0.01) worse for nonsurvivors, compared with survivors (Figure 1).

Figure 1
Figure 1

Box-and-whisker plots of the lowest serum glucose concentrations recorded during hospitalization for 57 dogs that were euthanized or died (n = 45) because of α-amanitin toxicosis or survived (12) with treatment for α-amanitin toxicosis from 2006 to 2019 at a northern California veterinary emergency and specialty hospital. Survivors had lowest serum glucose concentrations that were significantly (P < 0.05) higher than nonsurvivors. The horizontal line within each box represents the median, boxes represent the interquartile (25th to 75th percentile) range, and whiskers indicate the maximum and minimum values. The black dot indicates an outlier.

Citation: Journal of the American Veterinary Medical Association 258, 5; 10.2460/javma.258.5.502

Prothrombin time and aPTT were determined for 55 (93%) dogs with an in-hospital analyzer because of suspected development of liver failure; 4 dogs did not undergo coagulation testing because they were euthanized at initial presentation. Results for 5 dogs were initially within reference intervals, but coagulation times became prolonged during hospitalization (Table 1). All evaluated dogs had prolongation of PT, aPTT, or both during hospitalization, with 35 (64%) dogs having had PT or aPTT results that were > 100 or 300 seconds, respectively.

Amanitin testing

α-Amanitin was detected in the urine of 57 dogs (positive, 37; trace, 20) and not detected in the urine of 2 dogs that did not survive (Table 2). Outcome was significantly (P < 0.01) associated with the amount of detectable α-amanitin in urine, with 34 of 46 (74%) nonsurvivors testing positive for α-amanitin in urine versus 3 of 13 (23%) survivors.

Table 2

Urine α-amanitin test results for the dogs of Table 1.

Result No. of dogs Nonsurvivors Survivors
Negative 2 2 (4%) 0 (0%)
Trace 20 10 (22%) 10 (77%)
Positive 37 34 (74%) 3 (23%)
Total 59 46 (100%) 13 (100%)

Treatments

Nine (15%) dogs were euthanized once liver failure was identified on initial evaluation. Fifty (85%) dogs were admitted to the hospital for treatment, which included supportive care, decontamination, and α-amanitin–directed treatment. Supportive care entailed IV administration of lactated Ringer solution for treatment of hypovolemic shock and maintenance of hydration, dextrose supplementation for hypoglycemic patients (2.5% to 5% dextrose; constant rate infusion, IV), and treatment of comorbidities (eg, maropitant [1 mg/kg {0.45 mg/lb}, IV, q 24 h] for vomiting, pantoprazole or famotidine [1 mg/kg, IV, q 12 h] for gastric ulceration, ampicillin-sulbactam [30 mg/kg {13.6 mg/lb}, IV, q 8 h] for possible bacterial infection, and lactulose [1 to 3 mL, PO, q 8 h] for clinical signs of hepatic encephalopathy).

Because most dogs had vomited prior to presentation or were actively vomiting when presented to the hospital, induction of emesis was rarely indicated, but decontamination with oral administration of activated charcoal was attempted in 18 dogs to ameliorate enterohepatic recirculation of α-amanitin. Activated charcoal was administered as boluses 2 to 3 times a day or via slow infusion through an indwelling nasogastric tube for 1 to 3 days. Activated charcoal was not administered to the remaining dogs because of protracted vomiting or obtundation.

Direct hepatic support was provided with silybin (5 to 50 mg/kg/d [2.3 to 22.7 mg/lb/d], divided to q 8 h or q 12 h) in 39 dogs, N-acetylcysteine in 35 dogs, and both in 32 dogs. N-acetylcysteine was administered according to an established protocol for acetaminophen toxicosis.18 Fresh frozen plasma was administered to 41 dogs with coagulopathies. Most often, fresh frozen plasma was administered at 10 mL/kg (4.5 mL/lb) over 4 hours, then at 2 mL/kg/h (0.9 mL/lb/h), regardless of whether overt hemorrhage was evident. Twenty-four dogs were also supplemented with vitamin K1 (1 mg/kg, SC, q 12 h) during hospitalization. Treatments varied among patients.

Case outcomes

Of the 50 treated dogs, 13 (26%) survived to discharge. These 13 dogs were hospitalized for 1.25 to 5 days and discharged when they were eating, seemed comfortable, and were no longer dependent on dextrose to maintain normoglycemia. However, serum ALT activity remained markedly increased at discharge.

Only a few continuous variables were normally distributed, so the Wilcoxon rank sum test was used for all comparisons. Dogs that survived to discharge (vs those that were euthanized or had died) had significantly more hours elapse from the onset of clinical signs to resolution (ie, euthanasia, death, or discharge), higher serum glucose concentrations during hospitalization, lower BUN concentrations at presentation, less prolongation of PT and aPTT during hospitalization, and trace α-amanitin detected in the urine (Table 1). Serum ALT activity at presentation and its highest activity during hospitalization were not significantly different between survivors and nonsurvivors.

The remaining 46 (78%) patients were euthanized (n = 40) or died (6) in the hospital. The decision to euthanize was based on a poor response to treatment, owner financial constraints, or a grave prognosis because of deteriorating mental status (progression to obtundation). Most of the 50 dogs admitted to the hospital for treatment had financially committed owners, and their dogs were euthanized because of a poor prognosis. Five dogs that were euthanized had received treatment in the hospital for > 4 days.

Discussion

The retrospective study presented here provided a summary of the signalment; physical examination findings; results of serum biochemical analyses, coagulation tests, and a urine α-amanitin test; treatments; and outcomes for dogs that presented to an emergency and specialty veterinary hospital in northern California with amanitin toxicosis and provided a comparison of factors between dogs that survived to hospital discharge and dogs that were euthanized or died.

In the present study, the largest number of cases was in 2014 (n = 21), presumably attributable to variations in weather conditions, including precipitation. Multiple α-amanitin–containing mushroom species, including A ocreata and Galerina marginata, are present in northern California. The most common species is A phalloides, but some dogs may have ingested these other α-amanitin–containing mushrooms, because the test for detecting α-amanitin cannot distinguish between toxin from A phalloides and toxin from other mushroom species. For example, dogs with α-amanitin toxicosis in the winter and spring may have ingested A ocreata because A ocreata appears during these seasons. The California Poison Control Center did not identify an obvious increase in cases of human amanitin toxicosis in 2014,b but clusters of cases during particular years have been previously reported,8,10 including a cluster of 14 cases in the San Francisco Bay Area in 2016. The present study, however, did not reveal a correspondingly high number of dog cases in 2016 (n = 5). Awareness of case clusters of α-amanitin toxicosis could make this toxicosis the leading differential diagnosis and enable veterinarians to warn their clients of the risk of toxicosis in the area.

In veterinary medicine, diagnosis of α-amanitin toxicosis is often hindered because mushroom ingestion is rarely witnessed by a dog owner and testing for the presence of α-amanitin is uncommonly performed. In the present study, only 4 owners were aware that their dogs had eaten a mushroom. In areas where toxic mushrooms are prevalent, owners should be educated to monitor their pets closely for possible mushroom ingestion. If mushroom fragments are available, they can be submitted for α-amanitin detection or the mushroom species can be identified through PCR assay.19 Most dogs present relatively late in the course of toxicosis, such that it can only be definitively diagnosed by detection of α-amanitin. Confirmation of the toxin's presence is important because it can aid veterinarians in the treatment of the affected pet and inform owners of the risk of exposure for any other pets in the household. Additionally, confirmation could be a marker of how invasive mushroom species continue to expand throughout North America. A rapid lateral flow assay has been recently developed for the detection of α-amanitin in the urine of people and dogs,20 and such a test could make α-amanitin detection possible in the hospital, improving the ability to identify affected dogs and begin appropriate treatment.

The present study revealed that dogs with trace (vs positive) urine α-amanitin had improved likelihood of survival. Whether this reflects a lower toxic dose, improved toxin clearance, or a delay in obtaining the sample for analysis is unknown.

The clinical course of α-amanitin toxicosis is multiphasic.1,21 During a latency period of 6 to 24 hours after ingestion, clinical signs are usually absent. Physicians use a patient's report of a latency period to help them differentiate A phalloides poisoning from other mushroom poisonings, which typically cause vomiting within 1 to 2 hours of ingestion. During the gastrointestinal phase of toxicosis, vomiting, intestinal cramping, and diarrhea last 12 to 24 hours, secondary to enterocyte membrane damage by biologically active phallotoxins. After the gastrointestinal phase, about 36 to 48 hours after mushroom ingestion, is a convalescent phase during which clinical signs abate. The final phase is α-amanitin–induced liver and kidney failure, culminating in CNS dysfunction secondary to hepatic encephalopathy and cerebral edema.

In the present study, the time of mushroom ingestion was rarely known, and the distinct phases of illness were not always identified. In the 4 cases in which mushroom fragments were pulled from dogs' mouths, clinical signs were not noted until 12 to 24 hours after ingestion, consistent with the latency period reported in people. Only 13 (22%) dogs went through a recognizable convalescent phase before progression to liver failure. Presumably, some owners ignored or simply did not identify mild gastrointestinal signs in their dogs. Possibly, however, dogs have increased susceptibility to α-amanitin toxicosis or they ingest comparatively higher amounts of toxin (vs people), resulting in a more rapid progression to fulminant liver failure. An immediate progression from severe gastroenteritis to fulminant organ failure has been described in people with severe toxicosis, and clinical signs are likely dose dependent. By the time most dogs in the present study were brought to the hospital, clinical and biochemical evidence of liver failure was already present. Because of the inconsistency to recognize the distinct phases of α-amanitin toxicosis, whether those phases are even present for dogs, and possible differences in the ingested amounts of toxin between people and dogs, identification of distinct phases of toxicosis should not be attempted to screen dogs for toxicosis.

The dogs of the present study had increased serum activities of ALT and ALP, hypoglycemia, coagulopathy, and encephalopathy attributable to acute, extensive hepatocellular necrosis and subsequent compromised hepatic blood flow and bile production. These signs of liver failure are not specific to α-amanitin toxicosis; however, early-onset hypoglycemia was a distinguishing biochemical abnormality.

Forty-six of 57 (81%) dogs were found to be hypoglycemic at presentation, and 7 of the remaining 11 dogs became hypoglycemic during hospitalization. α-Amanitin depletes hepatic glycogen in people and animals,22 and this mechanism is the most likely explanation for the early-onset hypoglycemia noted in the dogs of the present study. A second possible mechanism of hypoglycemia is α-amanitin–induced insulin release from pancreatic beta cells.23 In 1 hypoglycemic dog reported here, a serum insulin-to-glucose ratio was determined at admission to the hospital, and insulin concentration was undetectable (< 2 μU/mL; reference interval, 5.2 to 41.5 μU/mL), which was an expected result with marked hypoglycemia (< 60 mg/dL) and, therefore, a result inconsistent with α-amanitin–induced insulin release. However, study is needed on the role of α-amanitin on insulin release from the pancreatic beta cells and hypoglycemia in affected dogs.

Identification of hypoglycemia helped to distinguish affected dogs from those with other causes of gastroenteritis. Six dogs in the present study were initially treated as outpatients for suspected gastroenteritis, yet returned to the hospital within 24 hours with progressive clinical signs. At initial presentation, these dogs had serum glucose concentrations within reference intervals or did not have serum biochemical analyses performed. When a vomiting dog was hypoglycemic, α-amanitin toxicosis was considered as a differential diagnosis; other differential diagnoses included xylitol toxicosis, severe anaphylaxis, sepsis, and porto-systemic shunt. Some clinicians were concerned that some of the 22 (37%) dogs with rectal temperatures > 39.2°C had sepsis because they did not expect dogs with toxicosis to present with high rectal temperatures. Although hypoglycemia was significantly worse during hospitalization for nonsurvivors, the decision on whether to treat should not be solely influenced by the presence of marked hypoglycemia because 5 of the 13 surviving dogs presented with serum glucose concentrations of 20, 30, 44, 45, and 72 mg/dL.

In this study, serum ALT activity was increased but highly variable. Surprisingly, ALT activity did not significantly differ between survivors and nonsurvivors. Although 27 (46%) dogs had ALT activity > 10,000 U/L, some dogs that had ALT activity < 10,000 U/L progressed to fulminant liver failure. Thirteen (22%) dogs had ALT activity < 500 U/L at initial evaluation. Because the clinical course of α-amanitin toxicosis is rapid, mild to moderate (vs severe) hepatocellular damage, as denoted by ALT activity, does not exclude α-amanitin toxicosis. For this reason, ALT activity may not have significantly differed between survivors and nonsurvivors.

Coagulation testing was performed for 55 dogs, and results for all dogs were abnormal at least once during hospitalization. The time of testing varied in relation to α-amanitin exposure because of the variability in time between the onset of clinical signs and presentation to the hospital. Also, coagulation tests were not part of the minimum database, and clinicians ordered coagulation testing only once they suspected liver failure. Prolongation of PT and aPTT during hospitalization was greater for nonsurvivors, compared with survivors, but was not significantly different at presentation. However, deciding whether to euthanize solely on the basis of prolonged PT and aPTT may be erroneous because many of the survivors had evidence of coagulopathies.

Despite years of research and experience, treatment of people with α-amanitin toxicosis is not standardized7; treatments frequently include decontamination, supportive care, and mitigation of enterohepatic recirculation and transport of α-amanitin into hepatocytes.7,24 For people and dogs, decontamination and mitigation of enterohepatic recirculation are frequently limited by the delay between mushroom ingestion and presentation at the hospital. Although decontamination is often initiated at presentation, studies7 of α-amanitin kinetics reveal that plasma concentrations of α-amanitin are low, urinary excretion of toxin is rapid, and decontamination is most valuable in the first 12 to 24 hours after mushroom ingestion. However, α-amanitin undergoes enterohepatic recirculation, so some physicians advocate for aggressive and prolonged decontamination, such as administration of multiple doses of activated charcoal.11 Only 18 (31%) dogs in the present study were administered activated charcoal.

Other methods of disrupting enterohepatic recirculation of toxins that have been investigated include administration of cholestyramine to adsorb bile acids and octreotide to reduce gallbladder motility and performance of biliary drainage procedures.8,11,24,25 Placement of biliary drainage catheters is challenging in veterinary patients because of small patient size, gallbladder anatomy, and limited access to needed instrumentation. Ultrasound-guided cholecystocentesis is commonly performed in veterinary medicine.26 However, it may be risky for patients with coagulopathies, and unlike a biliary drainage catheter, the procedure only allows for 1-time rather than continuous biliary drainage. Ultrasound-guided cholecystocentesis was performed in only 3 dogs in the present study because the risk of bleeding was considered high, given that most dogs had prolonged PT and aPTT by the time α-amanitin toxicosis was suspected or diagnosed. Also, the benefit of 1-time removal of only a small amount of bile was likely low, considering that studies15,21 show biliary excretion of α-amanitin accounts for < 10% to 20% of its excretion. Although dogs with indwelling biliary drainage catheters placed prior to experimental ingestion of Amanita mushrooms had less severe toxicosis (vs those without biliary drainage catheters), it was likely because of poor toxin absorption from the small intestine without the aid of bile, not because biliary drainage prevented or lessened enterohepatic recirculation of toxin.26 Clinical assessment of the impact of cholecystocentesis on patient outcomes is lacking and merits additional research. Cholecystocentesis may be helpful for patients identified within the first 24 hours of toxicosis. Although cholecystocentesis was performed in 3 dogs, none of these dogs survived (all 3 were euthanized).

Because α-amanitin is filtered through the glomeruli, maintaining urine output is essential for its elimination. However, diuresis through IV administration of crystalloid fluids or administration of loop diuretics (eg, furosemide) does not increase α-amanitin elimination or alter outcome. Also, hemodialysis and hemoperfusion are ineffective in eliminating toxin.27 All treated dogs in the present study were administered lactated Ringer solution (IV) to correct hypovolemia secondary to fluid loss through the gastrointestinal tract and hypovolemic shock and, later, to maintain normovolemia. Additionally, dogs received treatments that addressed hypoglycemia and signs of nausea and received antimicrobials (IV), a standard practice for people with acute liver failure or hepatic encephalopathy because of increased risk of sepsis and multiorgan failure.27 Many dogs were also administered lactulose orally, although lactulose may have little benefit in people for resolving hepatic encephalopathy secondary to acute liver failure.28 Patients with acute liver failure can develop cerebral edema and intracranial hypertension.28 These changes inevitably contributed to the progression of hepatic encephalopathy in several dogs of the present study, and when dogs became obtunded (excluding hypoglycemia-induced obtundation that resolved with restoration of euglycemia), they were euthanized or died.

A review7 of > 2,000 cases of human α-amanitin toxicosis in North America and Europe revealed that treatments associated with better outcomes included silybin and N-acetylcysteine.28 Silybin has a direct protective effect in α-amanitin toxicosis.13,29,30 Silybin is the most potent of the flavonoligans in silimarin, which is derived from milk thistle. Silybin has poor bioavailability, but its absorption after oral administration improves when it is complexed with phosphatidylcholine, thus creating a lipophilic-phytosome complex.31,32 In people, silybin inhibits the transporter system OATP1B3 that transports α-amanitin into hepatocytes, such that hepatocyte uptake of α-amanitin is mitigated.13 Silybin may also be beneficial by inhibiting proinflammatory tumor necrosis factor-α, disrupting enterohepatic recirculation, and stimulating intrahepatocellular protein synthesis.33

Silybin is protective in dogs when it is administered IV within 5 hours of α-amanitin ingestion.29,30 The efficacy of oral or delayed (> 5 hours) administration of silybin is unknown. Silybin is typically administered IV to people with α-amanitin toxicosis, with an initial dose of 5 mg/kg, then 20 mg/kg/d (9.1 mg/lb/d) as a constant rate infusion. A silybin productc has been available for IV administration in Europe since 1984 and is thought to be of benefit.33,34 People who are not administered silybin IV should be administered 20 to 50 mg/kg/d, PO.11

Through the years of the present study, attending clinicians increasingly believed in the importance of silybin as a treatment for dogs with α-amanitin toxicosis. Therefore, dogs with α-amanitin toxicosis after 2013 were managed with high and frequent doses of silybin. Dogs were administered high doses of silybin 2 to 4 hours prior to starting activated charcoal in an attempt to prevent silybin adsorption by the charcoal. Because the bioavailability of milk thistle products varies, administration of high doses of milk thistle complexed with phosphatidylcholine is recommended.31,32 Treatments varied in the present study, so their effect on patient outcome (survival vs nonsurvival) could not be compared.

Death rates of people with A phalloides toxicosis are between 10% and 30%.10 A review35 of 27 cases in San Francisco between 1997 and 2014 indicates fatal toxicosis in 3 (11%). Of the 50 dogs that were hospitalized for treatment in the present study, 37 (74%) were euthanized or died.

The 13 surviving dogs recovered fully and were assessed by their owners as healthy within 1 to 2 days after hospital discharge. Each returned for reexamination a few weeks later and had serum ALT activity and biochemical markers of liver function (eg, albumin, cholesterol, and bilirubin) within reference intervals. One dog developed mild azotemia 2 weeks after hospital discharge, but the azotemia resolved at a reexamination 1 month later. Of those dogs not lost to follow-up, many were doing well up to 5 years later.

The findings of the present study indicated that veterinarians should consider α-amanitin toxicosis when dogs present with severe gastrointestinal signs accompanied by increased serum ALT activity and hypoglycemia. If toxicosis is suspected, urine should be collected for toxin detection and supportive care should be initiated. Alanine aminotransferase activity was not significantly different between survivors and nonsurvivors; therefore, the magnitude of increased ALT activity should not be used for treatment (vs euthanasia) decision-making. Although death was frequent, the survival rate among dogs that were treated was 26%. Ongoing research in human and veterinary medicine might provide new treatment options to mitigate α-amanitin's effects and improve patient outcomes.

Acknowledgments

No external funding was used in this study. The authors declare that there were no conflicts of interest.

Abbreviations

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

aPTT

Activated partial thromboplastin time

ppb

Part per billion

PT

Prothrombin time

Footnotes

a.

Stata/SE 16.0, StataCorp LLC, College Station, Tex.

b.

Olson KR, California Poison Control System, San Francisco Division, San Francisco, Calif: Personal communication, 2016.

c.

Legalon SIL, Rottapharm Madaus GmbH, Cologne, Germany.

References

  • 1.

    Puschner B, Wegenast C. Mushroom poisoning cases in dogs and cats: diagnosis and treatment of hepatotoxic, neurotoxic, gastroenterotoxic, nephrotoxic, and muscarinic mushrooms. Vet Clin North Am Small Anim Pract 2018;48:10531067.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Puschner B, Rose HH, Filigenzi MS. Diagnosis of Amanita toxicosis in a dog with acute hepatic necrosis. J Vet Diagn Invest 2007;19:312317.

  • 3.

    Tegzes JH, Puschner B. Amanita mushroom poisoning: efficacy of aggressive treatment of two dogs. Vet Hum Toxicol 2002;44:9699.

  • 4.

    Tokarz D, Poppenga R, Kaae J, et al. Amanitin toxicosis in two cats with acute hepatic and renal failure. Vet Pathol 2012;49:10321035.

  • 5.

    Yee MM, Woods LW, Poppenga RH, et al. Amanitin intoxication in two beef calves in California. J Vet Diagn Invest 2012;24:241244.

  • 6.

    Garcia J, Costa VM, Carvalho A, et al. Amanita phalloides poisoning: mechanisms of toxicity and treatment. Food Chem Toxicol 2015;86:4155.

  • 7.

    Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715757.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Vo KT, Montgomery M, Mitchell T, et al. Amanita phalloides mushroom poisonings – Northern California, December 2016. MMWR Morb Mortal Wkly Rep 2017;66:549553.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Ammirati JF, Thiers HD, Horgen PA. Amatoxin-containing mushrooms: Amanita ocreata and A. phalloides in California. Mycologia 1977;69:10951108.

  • 10.

    Olson KR, Pond SM, Seward J, et al. Amanita phalloides-type mushroom poisoning. West J Med 1982;137:282289.

  • 11.

    Goldfrank LR. Mushrooms. In: Hoffman RS, Howland MA, Lewin NA, et al., eds. Goldfrank's toxicologic emergencies. 10th ed. New York: McGraw-Hill Education, 2015;15001514.

    • Search Google Scholar
    • Export Citation
  • 12.

    Faulstich H, Fauser U. The course of Amanita intoxication in Beagle dogs. In: Faulstich H, Kommerell B, Wieland T, eds. Amanita toxins and poisoning: International Amanita Symposium Heidelberg, November 1–3, 1978. Baden-Baden, Germany: Witzstrock, 1980;115120.

    • Search Google Scholar
    • Export Citation
  • 13.

    Letschert K, Faulstich H, Keller D, et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006;91:140149.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Jaeger A, Jehl F, Flesch F, et al. Kinetics of amatoxins in human poisoning: therapeutic implications. J Toxicol Clin Toxicol 1993;31:6380.

  • 15.

    Faulstich H, Talas A, Wellhöner HH. Toxicokinetics of labeled amatoxins in the dog. Arch Toxicol 1985;56:190194.

  • 16.

    Puschner B. Mushrooms. In: Peterson ME, Talcott PA, eds. Small animal toxicology. 3rd ed. St Louis: Elsevier Saunders, 2013;659676.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Filigenzi MS, Poppenga RH, Tiwary AK, et al. Determination of alpha-amanitin in serum and liver by multistage linear ion trap mass spectrometry. J Agric Food Chem 2007;55:27842790.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Sellon RK. Acetaminophen. In: Peterson ME, Talcott PA, eds. Small animal toxicology. 3rd ed. St Louis: Elsevier Saunders, 2013;423429.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Romano MC, Doan HK, Poppenga RH, et al. Fatal Amanita muscaria poisoning in a dog confirmed by PCR identification of mushrooms. J Vet Diagn Invest 2019;31:485487.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Bever CS, Swanson KD, Hamelin EI, et al. Rapid, sensitive, and accurate point-of-care detection of lethal amatoxins in urine. Toxins (Basel) 2020;12:123.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Sun J, Niu YM, Zhang YT, et al. Toxicity and toxicokinetics of Amanita exitialis in Beagle dogs. Toxicon 2018;143:5967.

  • 22.

    Kawaji A, Yamauchi K, Fujii S, et al. Effects of mushroom toxins on glycogenolysis; comparison of toxicity of phalloidin, alpha-amanitin and DL-propargylglycine in isolated rat hepatocytes. J Pharmacobiodyn 1992;15:107112.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    De Carlo E, Milanesi A, Martini C, et al. Effects of Amanita phalloides toxins on insulin release: in vivo and in vitro studies. Arch Toxicol 2003;77:441445.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Karvellas CJ, Tillman H, Leung AA, et al. Acute liver injury and acute liver failure from mushroom poisoning in North America. Liver Int 2016;36:10431050.

  • 25.

    Thiel C, Thiel K, Klingert W, et al. The enterohepatic circulation of amanitin: kinetics and therapeutical implications. Toxicol Lett 2011;203:142146.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Sun J, Zhang YT, Niu YM, et al. Effect of biliary drainage on the toxicity and toxicokinetics of Amanita exitialis in Beagles. Toxins (Basel) 2018;10:215.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Mullins ME, Horowitz BZ. The futility of hemoperfusion and hemodialysis in Amanita phalloides poisoning. Vet Hum Toxicol 2000;42:9091.

    • Search Google Scholar
    • Export Citation
  • 28.

    Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369:25252534.

  • 29.

    Vogel G, Tuchweber B, Trost W, et al. Protection by silibinin against Amanita phalloides intoxication in Beagles. Toxicol Appl Pharmacol 1984;73:355362.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Floersheim GL, Eberhard M, Tschumi P, et al. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharmacol 1978;46:455462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193203.

    • Search Google Scholar
    • Export Citation
  • 32.

    Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 2007;30:132138.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Mengs U, Pohl RT, Mitchell T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 2012;13:19641970.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Hruby K, Csomos G, Fuhrmann M, et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983;2:183195.

  • 35.

    Bonacini M, Shetler K, Yu I, et al. Features of patients with severe hepatitis due to mushroom poisoning and factors associated with outcome. Clin Gastroenterol Hepatol 2017;15:776779.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 776 0 0
Full Text Views 2349 1554 100
PDF Downloads 1313 459 27
Advertisement